SAN DIEGO, CA / ACCESS Newswire / August 26, 2025 / Modular Medical, Inc. (MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump ...
-Proof of Concept Study in Rapid Acting GLP-1 to commence in October 2024 with data expected in November 2024 -Pre-clinical study to explore use of MODD1 pump as a personalized delivery system for ...
SAN DIEGO, CA / ACCESS Newswire / September 11, 2025 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch ...
Pre-clinical study to explore use of MODD1 pump as a delivery system for FDA-approved, short acting peptides, as a personalized alternative for people who discontinue long-acting GLP-1 formulations ...
SAN DIEGO, CA / ACCESS Newswire / August 4, 2025 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch ...
SAN DIEGO, CA / ACCESSWIRE / January 19, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), a development-stage, insulin delivery technology company seeking to launch the ...
- Modular Medical (MODD) intends to deploy the MODD1 on a larger number of clinicians in mid August SAN DIEGO, CA / ACCESS Newswire / August 6, 2025 / Modular Medical, Inc. ("Modular Medical" or the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results